Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 22:11:555475.
doi: 10.3389/fphar.2020.555475. eCollection 2020.

Cardiovascular Complications of Prostate Cancer Treatment

Michał Wilk  1 , Anna Waśko-Grabowska  1 , Sebastian Szmit  2
Affiliations

Cardiovascular Complications of Prostate Cancer Treatment

Michał Wilk et al. Front Pharmacol. .

Abstract

Treatment of prostate cancer (PC) is a rapidly evolving field of pharmacology research. In recent years, numerous novel therapeutics that improve survival and ameliorate disease control have been approved. Currently, the systemic treatment for prostate neoplasm consists of hormonal therapy, chemotherapy, immunotherapy, radiopharmaceuticals, targeted therapy, and supportive agents (e.g., related to bone health). Unfortunately, many of them carry a risk of cardiovascular complications, which occasionally pose a higher mortality threat than cancer itself. This article provides a unique and comprehensive overview of the prevalence and possible mechanisms of cardiovascular toxicities of all PC therapies, including state-of-the-art antineoplastic agents. Additionally, this article summarizes available recommendations regarding screening and prevention of the most common cardiac complications among patients with advanced cancer disease.

Keywords: cardio-oncology; cardiovascular; complications; prostate cancer; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Alibhai S. M. H., Duong-Hua M., Sutradhar R., Fleshner N. E., Warde P., Cheung A. M., et al. (2009). Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J. Clin. Oncol. 27, 3452–3458. 10.1200/JCO.2008.20.0923 - DOI - PMC - PubMed
    1. Attard G., Reid A. H. M., Yap T. A., Raynaud F., Dowsett M., Settatree S., et al. (2008). Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26, 4563–4571. 10.1016/j.eururo.2008.08.043 - DOI - PubMed
    1. Attard G., Reid A. H. M., Auchus R. J., Hughes B. A., Cassidy A. M., Thompson E., et al. (2012). Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J. Clin. Endocrinol. Metab. 97, 507–516. 10.1210/jc.2011-2189 - DOI - PubMed
    1. Barbar S., Noventa F., Rossetto V., Ferrari A., Brandolin B., Perlati M., et al. (2010). A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the padua prediction score. J. Thromb. Haemostasis 8, 2450–2457. 10.1111/j.1538-7836.2010.04044.x - DOI - PubMed
    1. Beer T. M., Armstrong A. J., Rathkopf D. E., Loriot Y., Sternberg C. N., Higano C. S., et al. (2014). Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371, 424–433. 10.1056/NEJMoa1405095 - DOI - PMC - PubMed

LinkOut - more resources